PT-141 (Bremelanotide) – Synthetic Melanocortin Peptide

€160

PT-141 (Bremelanotide) – Synthetic Melanocortin Peptide

PT-141 (Bremelanotide) is a synthetic cyclic peptide belonging to the melanocortin family. It is studied for its interaction with MC3R and MC4R receptors, which are involved in central nervous system and neuroendocrine signalling.

Unlike conventional PDE5 inhibitors such as Sildenafil and Tadalafil, PT-141 acts through melanocortin receptor pathways rather than directly targeting vascular smooth muscle.

  • Synthetic cyclic heptapeptide
  • Melanocortin receptor agonist
  • Investigated in sexual desire and neuroendocrine research
  • Distinct mechanism from conventional PDE5 inhibitors

Research-grade material. Not approved for human or veterinary use. Not interchangeable with prescription Bremelanotide formulations.

PT-141 is ready to be shipped in 72 hours after payment. Average delivery time: 2–3 weeks.

Important: All products sold on this website are intended for research and forensic applications. For research use only. Not for human or veterinary use.

PT-141 (Bremelanotide) is a synthetic cyclic peptide belonging to the melanocortin family. It was developed through research into melanocortin receptor signalling and its influence on sexual motivation, neurological pathways and physiological responses.

Unlike conventional erectile dysfunction medications such as Sildenafil or Tadalafil, which primarily influence peripheral vascular mechanisms, PT-141 acts through the central nervous system.

Its primary pharmacological interest lies in its interaction with melanocortin receptors, particularly the MC3R and MC4R receptor subtypes.

Bremelanotide has been investigated for hypoactive sexual desire disorder (HSDD), and a prescription formulation has received regulatory approval in the United States for a specific indication in premenopausal women.

Chemical Identity & Structure

  • Compound name: Bremelanotide
  • Common designation: PT-141
  • Chemical class: Synthetic melanocortin peptide
  • Peptide type: Cyclic heptapeptide analogue
  • Molecular formula: C₅₀H₆₈N₁₄O₁₀
  • Molecular weight: Approximately 1025.2 g/mol
  • Parent research compound: Melanotan II
  • Primary receptor targets: MC3R and MC4R

PT-141 is structurally related to Melanotan II but has a modified peptide structure designed to retain melanocortin activity while reducing certain unwanted effects associated with its parent compound.

Mechanism of Action

PT-141 differs from conventional sexual-performance medications because its primary mechanism involves central melanocortin signalling rather than direct vascular stimulation.

Its pharmacological activity is associated with the following pathways:

1. Melanocortin Receptor Activation

PT-141 activates melanocortin receptors, particularly MC4R, which are involved in several neurological processes.

These receptors participate in:

  • Sexual motivation and behavioural signalling.
  • Central nervous system regulation.
  • Appetite and energy balance.
  • Neuroendocrine signalling.

2. Central Sexual Response Pathways

Melanocortin signalling is involved in neurological pathways associated with sexual desire and arousal.

Research suggests that activation of these pathways can influence sexual motivation independently of the peripheral vascular mechanisms targeted by PDE5 inhibitors.

3. Differences from PDE5 Inhibitors

Unlike Sildenafil and Tadalafil, PT-141 does not primarily work by inhibiting phosphodiesterase type 5.

This distinction makes it particularly interesting in research investigating central versus peripheral mechanisms of sexual function.

Pharmacological Research Profile

Bremelanotide is a non-selective melanocortin receptor agonist. According to its prescribing information, its receptor activity follows this approximate order:

  1. MC1R
  2. MC4R
  3. MC3R
  4. MC5R
  5. MC2R

At therapeutic exposure, MC1R and MC4R interactions are particularly relevant.

An important distinction is that although melanocortin receptor activation is established, the precise mechanism through which Bremelanotide improves sexual desire has not been fully determined.

Pharmacokinetics

Clinical studies of the approved injectable formulation have established several pharmacokinetic characteristics:

  • Absorption: Rapid absorption following subcutaneous administration.
  • Time to peak concentration: Approximately 1 hour.
  • Elimination half-life: Approximately 2.7 hours.
  • Metabolism: Peptide degradation into smaller peptide fragments and amino acids.
  • Elimination: Primarily through metabolic degradation and subsequent excretion.

These characteristics describe the approved pharmaceutical formulation and should not automatically be extrapolated to unverified research-grade preparations.

Research Applications

PT-141 is relevant to several areas of biomedical investigation:

  • Melanocortin receptor pharmacology.
  • Central nervous system signalling.
  • Sexual motivation and behavioural neuroscience.
  • Neuroendocrine regulation.
  • Hypoactive sexual desire disorder research.
  • Peptide structure–activity relationship studies.
  • Comparison of central and peripheral sexual-function mechanisms.

PT-141 Compared with Traditional ED Medications

CharacteristicPT-141SildenafilTadalafil
Active compoundBremelanotideSildenafilTadalafil
Drug classMelanocortin agonistPDE5 inhibitorPDE5 inhibitor
Primary mechanismCentral melanocortin signallingPDE5 inhibitionPDE5 inhibition
Main research interestSexual desire and CNS pathwaysErectile functionErectile function
Direct vascular mechanismNot primaryYesYes

The distinction is important: PT-141 investigates a different biological pathway from conventional PDE5 inhibitors.

Safety, Side Effects & Toxicological Considerations

Although Bremelanotide has undergone clinical investigation, its pharmacological activity is associated with several recognised adverse effects.

Commonly reported adverse reactions include:

  • Nausea.
  • Facial flushing.
  • Headache.
  • Vomiting.
  • Injection-site reactions.
  • Dizziness.
  • Fatigue.
  • Nasal congestion.

Important cardiovascular considerations

Bremelanotide can cause a temporary increase in blood pressure accompanied by a reduction in heart rate.

The approved pharmaceutical product is contraindicated in individuals with uncontrolled hypertension or known cardiovascular disease.

Other important considerations:

  • Focal hyperpigmentation can occur, particularly with repeated exposure.
  • Gastric emptying may be delayed.
  • The absorption of certain orally administered medications may be affected.
  • Particular attention is required when evaluating interactions with medications such as naltrexone.

Because research-grade peptide preparations are not necessarily equivalent to approved pharmaceutical products, their purity, sterility, concentration and stability must be independently established.

Dosage Information & Clinical Reference

The FDA-approved Bremelanotide formulation, marketed as Vyleesi in the United States, has a specific prescription indication for premenopausal women with acquired, generalized hypoactive sexual desire disorder.

Its approved pharmaceutical presentation contains 1.75 mg of Bremelanotide in a prefilled subcutaneous autoinjector.

This is a prescription-specific clinical formulation, not a general dosing recommendation for research peptides.

Important: There is no validated human dosing protocol for unapproved research-grade PT-141 powders or preparations. The approved product’s instructions should not be used to calculate doses from research vials.

Storage & Stability

Peptide stability depends on formulation, manufacturing quality and environmental conditions.

Important quality-control considerations include:

  • Protection from excessive heat.
  • Protection from moisture and direct light.
  • Verification of peptide identity and purity.
  • Assessment of degradation products.
  • Maintenance of appropriate storage conditions specified by the manufacturer.

Lyophilised peptide and reconstituted pharmaceutical solutions can have substantially different stability profiles. Storage periods should therefore be based on validated product-specific stability information rather than assumed shelf-life estimates.

Regulatory Status

Bremelanotide has received FDA approval in the United States under the brand name Vyleesi for a specific indication involving premenopausal women with acquired, generalized HSDD.

However, this approval does not extend automatically to:

  • Research-grade PT-141 powders.
  • Unapproved injectable preparations.
  • Other formulations or administration routes.
  • General treatment of erectile dysfunction in men.

Regulatory classification and availability vary between countries.

Summary

PT-141 (Bremelanotide) is a synthetic cyclic melanocortin peptide with a distinctive pharmacological profile involving central nervous system signalling.

Unlike conventional erectile dysfunction medications, which primarily target PDE5 and vascular smooth muscle, Bremelanotide interacts with melanocortin receptors involved in neuroendocrine and behavioural regulation.

Its clinical development and research applications make it an important compound in the study of sexual desire, melanocortin pharmacology and central sexual-response pathways.

Research-grade preparations should not be considered interchangeable with approved pharmaceutical Bremelanotide.

Dosage per Vial

5mg, 10mg

Quantity

10 Vials (1 Box)

Reviews

There are no reviews yet.

Be the first to review “PT-141 (Bremelanotide) – Synthetic Melanocortin Peptide”

Your email address will not be published. Required fields are marked *

SPIN TO WIN!

  • Try your luck and win a discount coupon code
  • 1 free spin every 15 days
  • No cheating! Please use your real email address only.
  • REMEMBER: The validity of the coupon code is 7 days.
Try Your Luck!
Never
Remind later
No thanks